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Osteoporosis is a term that encompasses both a risk factor for bone fragility (low bone density) and a condition of fragility (fractures). 1 About a third of new fractures come to medical attention, suggesting that, in reality, most are either asymptomatic or have tolerable symptoms. 2 These fractures, especially hip fractures, frequently result in a short-or long-term need for a higher level of care, and are associated with increased mortality. 3 
ALTERNATIVE TREATMENTS
Evidence for a role of calcium and vitamin D in preventing fractures are mainly confined to those with hypovitaminosis D or from aged care homes, with strong evidence of mild anti-fracture efficacy. 4 Given the adverse effects of prolonged oestrogen therapy, including an increased risk of myocardial infarction and breast cancer, 5 and the rare but potentially serious side-effects of common osteoporosis medications (bisphosphonates, raloxifene, denosumab and teriparatide), 6 the quest for alternative treatments to boost bone mineral density (BMD), and indeed to prevent fractures, have focused upon complementary treatments with a good safety profile, such as acupuncture.
Worldwide, acupuncture is integral to everyday medical practice. In recent decades its practice has gained popularity in Western countries. With increasing evidence of its clinical efficacy, acupuncture is now a widely practised treatment modality within complementary and integrative medicine. 7 After 40 years of extensive studies, compelling evidence has been obtained to support acupuncture as a useful tool for treating a wide spectrum of diseases. In fact, more than 40 disorders have been identified by the WHO as conditions that can benefit from acupuncture treatment. A study of 202 subjects attending an Australian university osteoporosis clinic found that almost one-fifth of those using a complementary medicine modality chose acupuncture. 8 The proportion using acupuncture is likely to be increasing over time.
POTENTIAL BENEFITS
The potential benefits of using acupuncture in osteoporosis can broadly be divided into two: (1) improvements in BMD; and (2) treatment of acute fracturerelated pain. Regarding the latter, there is reasonably strong evidence that acupuncture improves acute pain compared with sham acupuncture. 9 From a historical perspective, as highlighted by Wang et al, 10 the ancient classical text of acupuncture, Huangdi Neijing, "included a description of the 'Gallbladder Meridian of Foot Shaoyang (GB)' for treatment for bone diseases including 'bone-shaking and fragility', which was described as a systemic illness with multifocal bone pain and brittle bones that resembles contemporary osteoporosis". With this is mind, Wang et al 10 treated 37 osteoporotic female Wistar rats with electroacupuncture (EA) at GB points and were able to demonstrate reduced bone resorption, increased bone formation in BMD, and improved bone microarchitecture, even with a mild reduction in bodyweight. Previous nonhuman studies have also demonstrated improvements in BMD and bone strength, as well as hormonal profiles. Zhou et al 11 showed that early and late EA treatment increased serum oestradiol (E2) levels, reduced serum C-terminal telopeptide (CTX)-I levels, and increased BMD and bone strength of the L5 vertebral body in ovariectomised rats. Inoue et al 12 showed improved bone healing in rats in the form of a marked increase in cell count and expression of growth factor following EA and He et al 13 demonstrated that EA restored BMD towards normal and was associated with increased plasma E2 levels and reduced osteoprotegerin ligand (OPGL) expression in ovariectomised rabbits.
While the evidence that EA can have beneficial effects on osteoporosis is moderately convincing in ovariectomised animals, there are no such robust studies in humans. In one study of patients with spinal cord injuries, the results showed no statistically significant differences in BMD after 3 months of acupuncture treatment. 14 Overall, the findings support the potential role of EA in the management of osteoporosis, although robust clinical trials are needed to confirm the putative beneficial effects in postmenopausal women.
CHALLENGES
Finally there remain several challenges aside from the lack of convincing human data: (1) the ethical implications of conducting EA studies using the goldstandard comparator of sham acupuncture when there are many effective treatments for osteoporosis available; (2) the potentially enormous costs of conducting EA studies on human beings (with an adequately large sample size and over a sufficient time period) to detect differences in BMD and fractures; and (3) the safety profile of EA. Although case reports have highlighted major adverse events of acupuncture, such as organ puncture, infections and bleeding complications, more recently large cohort studies using universal precautions have not found a significant complication rate. Conversely, in a 2001 study of more than 34 000 acupuncture treatments in the UK, no serious adverse events (eg, hospitalisation, permanent disability, or death) were reported in relation to acupuncture therapy, and the rate of minor adverse events (eg, nausea, fainting, prolonged aggravation of existing symptoms, and psychological or emotional reactions) was reported to be between 0 and 1.1 per 10 000 treatments. 15 Ultimately, the evidence for EA in osteoporosis, while moderately convincing in non-human subjects, is at best scant for human beings. Rigorously applying the principles of evidence-based medicine, future studies of EA in human osteoporosis would ideally require the following: (1) the use of sham acupuncture as a comparator; (2) consideration of its potential as an adjunctive treatment to conventional osteoporosis treatments; (3) the inclusion of postmenopausal women with risk factors for osteoporosis as participants; (4) the use of BMD as a primary outcome, and vertebral and non-vertebral fractures as secondary outcomes; (5) evaluation of the safety profile and adverse effects (immediate and delayed) of EA; and, most importantly, (6) a standardisation of the EA procedure to ensure that multiple trials containing smaller numbers of participants can be effectively pooled to provide meaningful outcome information through meta-analysis. Effective pilot projects showing positive results (albeit with smaller numbers of participants) will ensure that larger randomised controlled trials of EA can be supported. Meanwhile, until further research evidence is available, the clinical use of EA for osteoporosis will remain in the realm of complementary and alternative medicine, and a recommendation for its routine use cannot be supported.
